Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.
- Home |
- Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
- September 23, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
